News | January 28, 2009

MRI with Ultrasound Identifies Breast Cancer Before Metastasis

MRI with Ultrasound Identifies Breast Cancer Before Metastasis

January 28, 2009 - A combination of MRI and ultrasound is able to measure the metabolism rates of cancer cells, according to research on a new technique developed by researchers at Tel Aviv University. The MRI-ultrasound technique has been refined for breast cancer identification so that each course of treatment is as individual as the woman being treated. The approach helps determine at an earlier stage than ever before which cells are metastasizing, and how they should be treated. The MRI-and-ultrasound-imaging application monitors the metabolic changes that occur during cancer metastasis. Increased blood flow (which can be sensed by ultrasound) and an increase of oxygen consumption (measured with an MRI) can indicate cancer metastasis with unprecedented levels of sensitivity. Normally scientists look for structural changes in the body, such as the presence of a tumor. But with their new methods, clinicains are able to “see” cancer metastasis within a small group of cells long before the cancer spreads to other organs in the body. “Today, clinicians only diagnose cancer when they see a tumor several millimeters in size. But our diagnosis can be derived from observing only a few cells, and looks specifically at the activation levels of a protein called Met. Activated Met is an oncogen,” said Ilan Tsarfaty, M.D., a lead researcher from TAU’s Sackler Faculty of Medicine. “If the tumor cells show activation of Met, we can design personalized medicine to treat a specific kind of breast cancer.” The method, expected to start clinical trials in 2010, is currently being researched in Israel hospitals. “We have developed a non-intrusive way of studying the metabolism of breast cancer in real time,” said Dr. Tsarfaty. “It’s an invaluable tool. By the time results are in from a traditional biopsy, the cancer can already be radically different. But using our technique, we can map the tumor and its borders and determine with high levels of certainty — right away — which patients should be treated aggressively.” “Current breast cancer treatments are not tailored to individual patients,” Dr. Tsarfaty said. “Our approach to profiling individual tumors will not only help save lives today, it will provide the basic research for developing cancer drugs of the future.” The research falls in a new field called "translational and personalized medicine.” The new research can be applied to all solid tumors, including those resulting from lung and brain cancer, and could be used to respond to a wide spectrum of neurodegenerative diseases, such as Alzheimer’s, Dr. Tsarfaty reported. Papers describing his methodologies were published recently in the journals Cancer Research and Neoplasia, and the Breast Cancer Research Foundation of America supports his research. Source: American Friends Tel Aviv University For more information: www.aftau.org

Related Content

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...